Amicus Therapeutics (NASDAQ:FOLD) reported quarterly sales of $88.10 million which beat the analyst consensus estimate of $86.29 million by 2.09 percent. This is a 7.23 percent increase over sales of $82.15 million the same period last year.
BlackRock Q2: Bottomline Beat, Net Inflow Strong At $80B, Continued Strength In Bond ETF Inflow
BlackRock Inc (NYSE: BLK) reported a Q2 revenue decline of 1% Y/Y to $4.46 billion, slightly below
